CKColleen R. Kelly

Colleen R. Kelly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Colleen R. Kelly has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Incidence and Risk Factors for C. difficile Reinfection After Faecal Microbiota Transplantation or Antibiotic Therapy

    by C. R. Kelly, B. J. Kelly, Q. Wu, L. Laine, G. D. Wu, A. Kim, L. Fredell, S. Serra, J. D. Lewis

    Background: Faecal microbiota transplant (FMT) is an effective treatment for multiply recurrent C. difficile infection (mrCDI). Less is known about rates of reinfection after successful FMT. We aimed to estimate the incidence of CDI reinfection, 6 or more months after FMT, to determine whether rates differ between mrCDI treated with and without FMT and whether proton pump inhibitor (PPI) therapy increases the risk of reinfection. Methods: Among patients with mrCDI (defined as ≥ 2 recurrences after the initial CDI episode) we compared reinfection with CDI (defined as a first recurrence > 183 days after treatment completion) in patients who underwent antibiotics followed by FMT with those treated with antibiotics alone in Optum's de‐identified Clinformatics Data Mart Database (OPTUM CDM). We also compared reinfection between those with and without PPI use in OPTUM CDM and the American Gastroenterological Association FMT Registry. Results: In OPTUM CDM, 6384 patients treated with antibiotics alone and 1786 with antibiotics + FMT met inclusion criteria (median follow‐up 704 days). One‐year and 3‐year CDI reinfection incidences were 5% and 10% in the FMT group and 6% and 12% in the antibiotics group: Cox regression HR 0.89, 95% CI 0.73–1.08. PPI use was associated with an increased risk of reinfection following FMT (HR 1.57, 1.03–2.41) in OPTUM CDM and in the FMT Registry (HR 1.62, 95% CI 0.84–3.12). Conclusions: CDI reinfection rates are low after successful FMT and similar to rates in patients treated with antibiotics alone. PPI use was associated with reinfection, supporting reassessment of the ongoing indication for PPI therapy in patients with mrCDI.


  • A Comparative Review of GI and ID Guidelines for Clostridioides difficile Treatment

    by Colleen R. Kelly

    Clostridioides difficile infection (CDI) is a leading healthcare-associated infection, primarily affecting older adults and patients with recent antibiotic exposure. Gastroenterology (GI) and infectious disease (ID) societies have developed separate guidelines reflecting their respective focuses. This review compares recommendations from the American College of Gastroenterology (ACG), Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA), and the American Gastroenterological Association (AGA). Both ACG and IDSA/SHEA endorse multistep diagnostic algorithms combining sensitive and specific assays, though IDSA permits PCR-only testing under strict criteria. For initial CDI, vancomycin and fidaxomicin are first-line agents, with IDSA’s 2021 update prioritizing fidaxomicin for reduced recurrence. Recurrent CDI management is similar, emphasizing fidaxomicin, tapered vancomycin, and fecal microbiota transplantation (FMT) after multiple recurrences. ACG and AGA provide greater specificity for FMT use and endorse microbiota-based therapies earlier in high-risk or treatment-refractory patients. Both guidelines (e.g., ACG and IDSA/SHEA) align on definitions and treatment for severe and fulminant CDI but diverge on prophylactic vancomycin and management in inflammatory bowel disease. Overall, the recommendations are largely concordant, with GI guidelines emphasizing fecal microbiota therapies and individualized care. Trials of defined synthetic consortia of bacteria are underway and may further alter the treatment landscape. Clinical trials and experience with these agents will inform future prevention and treatment algorithms as we move toward the safest and most effective therapeutic strategies for CDI.

  • Open Access

    Impact of switching from polymerase chain reaction-only to two-step Clostridioides difficile testing in a large hospital system

    by Sapana R. Gupta, Tyler M. Selig, Kathryn Evey, Michael Rossi, Adam M. Burton, Curtis Petruzzelli, Jacqueline J. Chu, Wen Ting Yang, James Scharfen, Joshua Ray Tanzer, et al.

    Introduction: Clostridioides difficile is the primary cause of healthcare-associated infectious diarrhea in hospitalized patients. The most common laboratory testing methods for C. difficile infection (CDI) are toxin detection via enzyme immunoassay (EIA) and polymerase chain reaction (PCR), which detect a toxogenic strain. This study examines the impact of Rhode Island’s largest hospital system changing from PCR-only to two-step CDI testing. Methods: A retrospective cohort study of 2,173 adult inpatients was conducted. Patients were grouped into two cohorts: those tested for toxigenic C. difficile via PCR-only (June 2019–May 2021, n = 1,194) and those tested with the two-step algorithm (June 2021–May 2023, n = 979). Cluster analysis identified patient risk groups for hypothesis generation, and complications such as death, colectomy, intensive care unit ICU transfer, and 30-day readmission were compared across these groups. Results: In the moderate-risk group, there was a significant reduction in ICU transfers and readmission rates with the two-step testing by 5% and 7%, respectively. There were no other significant differences in complications between testing groups. Anti-CDI antibiotics were discontinued in 15% ( n = 106) of EIA-negative patients in the two-step testing group. Moderate-risk patients were less likely to have treatment discontinued than severe-risk patients (OR = 2.00, p = 0.016). Discussion: The two-step testing algorithm did not negatively affect patient outcomes and led to a modest decrease in anti-CDI treatment, supporting the safety of two-step CDI testing in hospitalized patients.